Home / Caris Life Sciences: Nasdaq Debut, New CBO, & $168M Funding

Caris Life Sciences: Nasdaq Debut, New CBO, & $168M Funding

By: Jasmin Espinas
June 19, 2025

Caris Life Sciences is a molecular science company specializing in precision oncology. Its diagnostic and AI platforms are gaining traction among cancer researchers, health systems, and pharmaceutical partners, placing it in a strong position within the biotech sector.

This article covers three recent developments: Caris’ upcoming Nasdaq listing, the appointment of a new Chief Business Officer, and $168 million in private capital funding.

Latest News: Caris Life Sciences Debuts on Nasdaq With Strong $7.66 Billion Valuation

Caris Life Sciences surged nearly 29% in its Nasdaq debut on June 18, closing its first day with a valuation of $7.66 billion.

Caris Life Sciences is now officially trading on @Nasdaq under CAI.
This marks a major milestone as Caris takes another step forward in our mission to advance precision medicine and improve patient lives.
Learn more: https://t.co/t3xt1dvTBQ $CAI pic.twitter.com/aUrTA4scKj

— Caris Life Sciences (@carisls) June 18, 2025

At the same time, shares opened at $27, well above the $21 offer price, as the company raised $494.1 million by selling 23.5 million shares.

President David Spetzler said Caris plans to use the proceeds to reduce debt and fund strategic investments.

“We were waiting on hitting some key milestones,” he also noted in an interview.

Founded in 2008 by CEO David Halbert, the company applies AI to analyze DNA, RNA, and protein data to guide personalized cancer treatments.

Caris Life Sciences’ last valuation came in 2021 at $7.83 billion, led by Sixth Street.

Caris Life Sciences Appoints Eric Matthews as Chief Business Officer for Biopharma

Caris Life Sciences has appointed Eric Matthews as Chief Business Officer of Biopharma Business Development. He will lead the company’s efforts to expand and manage its biopharma partnerships.

Caris Life Sciences is pleased to announce that Eric Matthews has joined the organization as Chief Business Officer, Biopharma Business Development.

Learn more: https://t.co/Cy5htXUpJV pic.twitter.com/UquLl2kSse

— Caris Life Sciences (@carisls) May 8, 2025

Additionally, Matthews brings experience from senior roles across biotech and pharma, including his most recent position as Chief Commercial Officer at Arcus Biosciences.

Before these roles, he led global marketing for AstraZeneca’s immuno-oncology franchise and held leadership posts at Genentech, Roche, and GSK.

Caris Life Sciences Raises $168M in Private Capital to Expand AI-Driven Platform

On May 7, Caris Life Sciences closed a $168 million growth funding round to accelerate the development of its AI-based precision oncology platform.

The latest round brings the company’s total capital raised since 2018 to $1.86 billion.

Moreover, Braidwell LP, an existing investor focused on life sciences, led the financing. New participants included Perceptive Advisors, Woodline, and Ghisallo.

Additional backing came from returning investors such as Millennium Management and First Light Asset Management.

Vice Chairman Brian J. Brille said, “This financing includes participation by some of the most knowledgeable healthcare investors with deep domain expertise and appreciation of the Caris platform and opportunity.”

Conclusion

Caris Life Sciences is entering a new phase. Backed by institutional capital and a leadership bench with deep industry ties, the company is laying the groundwork to expand its influence in precision oncology.

Caris Life Sciences has closed a growth capital funding round of $168 million. With this funding, Caris has raised $1.86 billion in capital since 2018.
Learn more: https://t.co/5oJE8YQkiZ pic.twitter.com/7bi1N4ONA7

— Caris Life Sciences (@carisls) April 7, 2025

But, even with momentum, execution will need to match expectations. Investors and partners will also be watching closely as Caris moves through its next growth stage.

For ongoing coverage of Caris, similar companies, biotech updates, and business finance developments, subscribe to Financial Daily Update today.